| Literature DB >> 32546574 |
Louis Grandjean1,2,3, Joha Monteserin4, Robert Gilman2,5, Julia Pauschardt2, Sakib Rokadiya6, Cesar Bonilla7, Viviana Ritacco4, Julia Rios Vidal7, Julian Parkhill8, Sharon Peacock9, David Aj Moore10, Francois Balloux11.
Abstract
BACKGROUND: Understanding how pathogen genetic factors contribute to pathology in TB could enable tailored treatments to the most pathogenic and infectious strains. New strategies are needed to control drug-resistant TB, which requires longer and costlier treatment. We hypothesised that the severity of radiological pathology on the chest radiograph in TB disease was associated with variants arising independently, multiple times (homoplasies) in the Mycobacterium tuberculosis genome.Entities:
Keywords: clinical epidemiology; imaging/CT MRI etc; tuberculosis
Mesh:
Substances:
Year: 2020 PMID: 32546574 PMCID: PMC7361023 DOI: 10.1136/thoraxjnl-2019-213281
Source DB: PubMed Journal: Thorax ISSN: 0040-6376 Impact factor: 9.139
Clinical, demographic and pathogen data for the 103 isolates included in the study
| Variable | No. (%*†) |
| No. of patients | 103 |
| Male gender (%) | 71 (69) |
| Age | |
| 10–19 | 21 (20) |
| 20–29 | 46 (45) |
| 30–39 | 13 (13) |
| 40–49 | 11 (11) |
| 50–59 | 7 (7) |
| 60–69 | 2 (2) |
| 70–79 | 2 (2) |
| Missing | 1 (1) |
| HIV positive | 5 (5) |
| Radiological pathology % of lung involved (median/IQR) | 30 (15–50) |
| Drug susceptibility status | |
| Mono-resistant | 12 (12) |
| MDR | 91 (88) |
| Previous tuberculosis disease | 30 (29) |
| Lineage | |
| Lineage 2.2.1 | 7 (7) |
| Lineage 4 | 7 (7) |
| Lineage 4.1 | 1 (1) |
| Lineage 4.1.1 | 5 (5) |
| Lineage 4.1.1.3 | 4 (4) |
| Lineage 4.1.2.1 | 10 (10) |
| Lineage 4.3.2 | 4 (4) |
| Lineage 4.3.3 | 43 (42) |
| Lineage 4.3.4.1 | 4 (4) |
| Lineage 4.3.4.2 | 17 (16) |
| Lineage 4.8 | 1 (1) |
*% total 101 due to rounding.
†No missing data unless stated.
MDR, multidrug resistant .
Figure 1Study phylogeny with branches coloured by sublineage as defined by Coll et al. Clinical outcome following treatment is displayed (bad outcome: black dots, good outcome: grey dots on the tips of the tree) in a ring surrounding the phylogeny with the pathology on chest radiograph (% of lung with disease) represented by a circle of varying size according to the extent of pathology.
Figure 2The distribution of homoplastic polymorphisms identified in the study. A, adenine, G, guanine, C, cytosine, T, thymine, N, unknown (no call).
Homoplastic mutations identified in the dataset
| Reference position | Gene | Mutation | Homoplasies (n) | No. (Prevalence) | Reference base | Mutant base |
| 761160 |
| Ser450Leu | 13 | 54 (52%) | C | T |
| 2155176 |
| Ser315Thr | 10 | 71 (69%) | C | G/T |
| 4247436 |
| Met306Val | 9 | 13 (13%) | A | G |
| 1473254 |
| A1401G rRNA gene | 5 | 5 (5%) | A | G |
| 3135920 |
| Thr141Arg | 4 | 34 (33%) | G | C |
| 4247438 |
| Met306Ile | 4 | 16 (16%) | G | A/C/T |
| 766493 |
| Pro1040Arg | 3 | 3 (3%) | C | G/T |
| 761114 |
| Asp435Tyr | 3 | 3 (3%) | G | T |
| 761144 |
| His445Asp | 3 | 9 (9%) | C | G/T |
| 2123153 |
| Val3Ile | 3 | 13 (13%) | C | T |
Figure 3Distribution of radiograph pathology as a function of epidemiological and pathogen genetic variables; (A) previous episode of TB, rate ratio 1.2, p=<0.01; (B) age range 10–30 versus other ages, rate ratio 1.2, p<0.01; (C) gender, rate ratio 1.13, p=0.29; (D) rpoB 450; Rr 0.8, p=0.03; (E) rpoC.1040, Rr 1.97, p<0.01; (F) Rv2828c.141, Rr 1.3, p<0.01.
Variables in the multivariable predictive regression model of radiological pathology in multidrug-resistant tuberculosis with rate ratios and their associated lower and upper 95% CI, SE and p values
| Variable | Rate ratio | Upper CI | Lower CI | SE | P value* |
| Mutation | |||||
| katG.315 | 1.14 | 1.28 | 1.01 | 0.07 | 1.00 |
| rpoB.450 | 0.81 | 0.94 | 0.69 | 0.06 | 0.03 |
| rpoC.1040 | 1.97 | 2.16 | 1.77 | 0.10 | <0.01 |
| rpoB.435 | 1.21 | 1.40 | 1.01 | 0.10 | 1.00 |
| Rv2828c.141 | 1.30 | 1.39 | 1.21 | 0.04 | <0.01 |
| embB.306 | 0.86 | 0.97 | 0.74 | 0.06 | 0.27 |
| rpoB.445 | 1.09 | 1.25 | 0.93 | 0.08 | 1.00 |
| Male gender | 1.13 | 1.23 | 1.04 | 0.05 | 0.29 |
| HIV positive | 0.84 | 1.02 | 0.66 | 0.09 | 1.00 |
| Age 10–19 | Comparison | Comparison | Comparison | Comparison | Comparison |
| Age 20–29 | 0.97 | 1.08 | 0.87 | 0.05 | 1.00 |
| Age 30–39 | 0.66 | 0.82 | 0.50 | 0.08 | <0.01 |
| Age 40–49 | 0.93 | 1.08 | 0.78 | 0.08 | 1.00 |
| Age 50–59 | 1.20 | 1.37 | 1.02 | 0.09 | 1.00 |
| Age 60–69 | 0.71 | 1.04 | 0.38 | 0.17 | 1.00 |
| Age 70–79 | 0.43 | 0.79 | 0.07 | 0.18 | <0.01 |
| MDR | Comparison | Comparison | Comparison | Comparison | Comparison |
| Mono-resistant | 0.86 | 0.99 | 0.72 | 0.07 | 0.75 |
| Previous TB | 1.19 | 1.28 | 1.10 | 0.05 | <0.01 |
| Lineage 2 | Comparison | Comparison | Comparison | Comparison | Comparison |
| Lineage 4 | 1.28 | 1.49 | 1.08 | 0.10 | 0.48 |
| Lineage 4.1.1 | 1.32 | 1.54 | 1.10 | 0.11 | 0.33 |
| Lineage 4.1.1.3 | 1.06 | 1.34 | 0.78 | 0.14 | 1.00 |
| Lineage 4.1.2.1 | 1.34 | 1.52 | 1.16 | 0.09 | 0.05 |
| Lineage 4.3.2 | 1.15 | 1.40 | 0.89 | 0.13 | 1.00 |
| Lineage 4.3.3 | 1.02 | 1.18 | 0.87 | 0.08 | 1.00 |
| Lineage 4.3.4.1 | 0.61 | 0.89 | 0.33 | 0.14 | 0.02 |
| Lineage 4.3.4.2 | 1.26 | 1.43 | 1.08 | 0.09 | 0.27 |
| Lineage 4.8 | 0.98 | 1.39 | 0.57 | 0.21 | 1.00 |
*Bonferroni-corrected p value.